Abstract
Tissue transglutaminase (tTG) is a Ca2+-dependent enzyme which stabilizes the extracellular matrix (ECM) through post-translational modification, and may play an important role in the pathogenesis of focal and segmental glomerulosclerosis (FSGS). Here, we have investigated whether tTG contributes to the glomerular ECM expansion in the puromycin aminonucleoside (PAN)-injection-induced experimental rat model of FSGS. The localization and expression of tTG, MMP-9 gelatinase, and the ECM component fibronectin (FN) in kidneys was determined by immunohistochemistry and measured by semi-quantitative analysis. Protein levels of tTG and MMP-9 were also analyzed by Western blotting.In situtransglutaminase activity was assayed by measurement of incorporated substrate and the immunofluorescence staining for the cross-linking product, ε-(γ-glutamyl) lysine. Prominent proteinuria, a typical pathological feature of FSGS, was observed in PAN injection group rats. tTG immunoreactivity was located markedly in glomeruli and the levels of this protein in whole-kidney homogenates of PAN injection group rats were significantly increased (361± 106% control, P< 0.05). Similarly, transglutaminase activity and ε-(γ-glutamyl) lysine were also predominately located within glomeruli and were much more intense in the PAN-injected group than that in control animals. MMP-9 was also located primarily within glomeruli. In PAN-injected kidneys, protein levels of active MMP-9 were significantly reduced (59± 27% control, P< 0.01), while pro-MMP-9 levels increased (148± 42% control, P< 0.05). Remarkable expression of glomerular fibronectin (FN) was found in PAN injection group rats. Semi-quantitative analysis demonstrated this increased intensity of FN staining in the PAN-injected rats was 149± 23% of the control values (P< 0.05). Enhanced cross-linking of ECM by tissue transglutaminase and decreased degradation due to reduced active MMP-9 expression may be at least partially responsible for the deposition of FN within injured glomeruli in experimental FSGS.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Fogo AB: Mesangial matrix modulation and glomerulosclerosis. Exp Nephrol 7: 147–159, 1999
Yang Y, Zhang SY, Sich M, Beziau A, van den Heuvel LP, Gubler MC: Glomerular extracellular matrix and growth factors in diffuse mesangial sclerosis. Pediatr Nephrol 16: 429–438, 2001
Schnaper HW: Balance between matrix synthesis and degradation: a determinant of glomerulosclerosis. Pediatr Nephrol 9: 104–111, 1995
Jacot TA, Striker GE, Stetler-Stevenson M, Striker LJ: Mesangial cells from transgenic mice with progressive glomerulosclerosis exhibit stable, phenotypic changes including undetectable MMP-9 and increased type IV collagen. Lab Invest 75: 791–799, 1996
Shiozawa S: Participation of macrophages in glomerular sclerosis through the expression and activation of matrix metalloproteinases. Pathol Int 50: 441–57, 2000
Johnson TS, Griffin M, Thomas GL, Skill J, Cox A, Yang B, Nicholas B, Birckbichler PJ, Muchaneta-Kubara C, Meguid El Nahas A: The role of transglutaminase in the rat subtotal nephrectomy model of renal fibrosis. J Clin Invest 99: 2950–2960, 1997
Mirza A, Liu SL, Frizell E, Zhu J, Maddukuri S, Martinez J, Davies P, Schwarting R, Norton P, Zern MA: A role for tissue transglutaminase in hepatic injury and fibrogenesis, and its regulation by NF-kappaB. Am J Physiol 272: G281–288, 1997
Griffin M, Casadio R, Bergamini CM: Transglutaminases: nature's biological glues. Biochem J 368: 377–396, 2002
Aeschlimann D, Thomazy V: Protein crosslinking in assembly and remodelling of extracellular matrices: the role of transglutaminases. Connect Tissue Res 41:1–27, 2000
Fesus L, Piacentini M: Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci 27: 534–539, 2002
Skill NJ, Griffin M, El Nahas AM, Sanai T, Haylor JL, Fisher M, Jamie MF, Mould NN, Johnson TS: Increases in renal ε-(γ-glutamyl)-lysine crosslinks result from compartment-specific changes in tissue transglutaminase in early experimental diabetic nephropathy: pathologic implications. Lab Invest 81: 705–716, 2001
Johnson TS, Skill NJ, El Nahas AM, Oldroyd SD, Thomas GL, Douthwaite JA, Haylor JL, Griffin M: Transglutaminase transcription and antigen translocation in experimental renal scarring. J Am Soc Nephrol 10: 2146–2157, 1999
Johnson TS, El-Koraie AF, Skill NJ, Baddour NM, El Nahas AM, Njloma M, Adam AG, Griffin M: Tissue transglutaminase and the progression of human renal scarring. J Am Soc Nephrol 14: 2052–2062, 2003
Diamond JR, Karnovsky MJ: Focal and segmental glomerulosclerosis following a single intravenous dose of puromycin aminonucleoside. Am J Pathol 122: 481–487, 1986
Noel LH: Morphological features of primary focal and segmental glomerulosclerosis. Nephrol Dial Transplant 14(suppl 3): 53–57, 1999
Knowlden J, Martin J, Davies M, Williams JD: Metalloproteinase generation by human glomerular epithelial cells. Kidney Int 47: 1682–1689, 1995
Asanuma K, Shirato I, Ishidoh K, Kominami E, Tomino Y: Selective modulation of the secretion of proteinases and their inhibitors by growth factors in cultured differentiated podocytes. Kidney Int 62: 822–831, 2002
Ortmann J, Amann K, Brandes RP, Kretzler M, Munter K, Parekh N, Traupe T, Lange M, Lattmann T, Barton M: Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after Endothelin inhibition. Hypertension 44: 974–981, 2004
Schaefer L, Han X, August C, Matzkies F, Lorenz T, Schaefer RM: Differential regulation of glomerular gelatinase B (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in obese Zucker rats. Diabetologia 40:1035–1043, 1997
Ma LJ, Jha S, Ling H, Pozzi A, Ledbetter S, Fogo AB: Divergent effects of low versus high dose anti-TGF-beta antibody in puromycin aminonucleoside nephropathy in rats. Kidney Int 65: 106–115, 2004
Smeets B, Te Loeke NA, Dijkman HB, Steenbergen ML, Lensen JF, Begieneman MP, van Kuppevelt TH, Wetzels JF, Steenbergen EJ: The parietal epithelial cell: a key player in the pathogenesis of focal segmental glomerulosclerosis in Thy-1.1 transgenic mice. J Am Soc Nephrol 15: 928–939, 2004
Dreier R, Grassel S, Fuchs S, Schaumburger J, Bruckner P: Pro-MMP-9 is a specific macrophage product and is activated by osteoarthritic chondrocytes via MMP-3 or a MT1-MMP/MMP-13 casecade. Exp Cell Res 297: 303–312, 2004
Ritter SJ, Davies PJA: Identification of a Transforming Growth Factor-b1/Bone Morphogenetic Protein 4 (TGF-b1/BMP4) Response Element within the Mouse Tissue Transglutaminase Gene Promoter. J Biol Chem 273: 12798–12806, 1998
Endlich N, Sunohara M, Nietfeld W, Wolski EW, Schiwek D, Kranzlin B, Gretz N, Kriz W, Eickhoff H, Endlich K: Analysis of differential gene expression in stretched podocytes: osteopontin enhances adaptation of podocytes to mechanical stress. FASEB J 16: 1850–1852, 2002
Lee LK, Meyer TW, Pollock AS, Lovett DH: Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. J Clin Invest 96: 953–964, 1995
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liu, S., Li, Y., Zhao, H. et al. Increase in extracellular cross-linking by tissue transglutaminase and reduction in expression of MMP-9 contribute differentially to focal segmental glomerulosclerosis in rats. Mol Cell Biochem 284, 9–17 (2006). https://doi.org/10.1007/s11010-005-9005-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11010-005-9005-6